Lett, Martin Joseph https://orcid.org/0000-0002-7230-9264
Otte, Fabian https://orcid.org/0000-0003-0572-617X
Hauser, David https://orcid.org/0000-0001-9950-365X
Schön, Jacob https://orcid.org/0000-0002-9801-7972
Kipfer, Enja Tatjana https://orcid.org/0000-0001-5870-6784
Hoffmann, Donata https://orcid.org/0000-0003-4552-031X
Halwe, Nico J. https://orcid.org/0000-0002-7983-2808
Breithaupt, Angele https://orcid.org/0000-0002-6373-5923
Ulrich, Lorenz https://orcid.org/0000-0001-5004-806X
Britzke, Tobias https://orcid.org/0009-0001-8177-4766
Kochmann, Jana
Corleis, Björn
Zhang, Yuepeng https://orcid.org/0009-0009-7923-2173
Urda, Lorena https://orcid.org/0009-0007-4122-515X
Cmiljanovic, Vladimir
Lang, Christopher https://orcid.org/0000-0002-6052-6835
Beer, Martin https://orcid.org/0000-0002-0598-5254
Mittelholzer, Christian https://orcid.org/0000-0003-4353-3555
Klimkait, Thomas https://orcid.org/0000-0003-4945-6511
Article History
Received: 5 March 2024
Accepted: 10 October 2024
First Online: 30 October 2024
Competing interests
: V.C. owns shares of RocketVax AG, Basel, CH. The other authors declare no competing interests. A patent application (no. WO 203/036947 A1) has been filed on the topic of this vaccine.